February 26, 2019 –

WuXi NextCODE to Offer The New Pan-Cancer TSO 500 Biomarker Assay from Illumina

WuXi NextCODE offers access to Illumina's TruSightTM Oncology 500 (TSO 500).

WuXi NextCODE partners are gaining access to Illumina’s TruSightTM Oncology 500 (TSO 500), a comprehensive pan-cancer assay that identifies known and emerging tumor biomarkers.

TSO 500 offers deep, adaptable, and accessible sequencing power:

  • Comprehensive oncology testing: The TSO 500 covers gene alterations used to identify patients for clinical trials including 1.94Mb of the genome to measure tumor mutational burden (TMB).
  • Unlocks immunotherapy research: The highly accurate TMB and microsatellite instability (MSI) algorithms, with a dedicated tumor-only workflow, detect the majority of known genetic variants, whether small variants, gene amplifications, de novo fusions, or splice variants.
  • Integrated RNA+DNA workflow: Covering RNA and DNA biomarkers in one workflow lets labs evaluate multiple biomarkers at once. This tumor-only workflow enables cost savings, since there is no need to run a normal sample each time.

With the upcoming opening of a WuXi NextCODE laboratory in Woburn, MA we are expanding our global CLIA/CAP lab footprint, which already includes Shanghai and Dublin, thereby empowering clinical trial/research testing around the world. Our US lab features a turn-around time of 7-10 calendar days from sample to data for the TSO 500 assay.

WuXi NextCODE’s end-to-end platform includes industry-leading cohort sourcing, sequencing services, advanced analysis, and related tools and services to generate high-value strategic insights needed for diagnostic and drug development.

If you’re interested in using the TSO 500 panel for your next project, contact sales@wuxinextcode.com.

Filter By:

Recent Posts